Through funding from the National Institute for Health and Care Research (NIHR), and in close collaboration with NIHR infrastructure and its counterparts in the devolved administrations, the ATTC network aims to build upon its existing work, expand its reach, and integrate its initiatives into standard practice. The primary focus will be on enhancing the readiness of advanced therapy clinical trials, with the goal of expanding capacity and capability across a broader network to bring more innovative therapies to patients and strengthen the UK’s appeal to industry.

NA-ATTC’s vision is to increase patient access to advanced therapy medicinal products (ATMPs) regionally and nationally. The centre has a population reach of circa 15 million spanning the North of England and Scotland and is working across two healthcare systems. The centre aims to develop best practice for safe and effective delivery of advanced therapies to patients.

The centre has worked to achieve this through:

• Developing best practice for safe and effective delivery of advanced therapies to patients, for example through tracking and tracing systems compliant with regulatory standards.
• Mapping and improving NHS readiness levels for disruptive advanced therapies within the NA-ATTC.
• Development of a harmonised clinical trials toolbox for procedures and processes, innovative training networks and novel ways to approach health and safety, including follow-up.

Location

The NA-ATTC works across the north of England (Leeds and Newcastle upon Tyne) and Scotland.

Leadership team

Professor Neil Watson, Clinical Director of Pharmacy and Medicines Optimisation and Co-Director of the NA-ATTC

Marc Turner, Co-Director

Finn Willingham, Operations Manager

Looking for more information?

Find details of how to contact this centre here